We use cookies and other similar technologies (Cookies) to enhance your experience and to provide you with relevant content and ads. By using our website, you are agreeing to the use of Cookies. You can change your settings at any time. Cookie Policy.


Urix Partners with Pharmacy Outcomes Specialists

Originally published February 15, 2006

Beginning in February 2006, individual states will begin paying the federal government the first monthly installment of a ten year liability estimated to range between $48 and $100 billion. This payback provision under the new Medicare drug program is commonly referred to as the "Part D claw back". The provision is intended to compensate the federal government for providing drug coverage to elderly or disabled low income residents who previously buy adderall received this coverage under Medicaid. These individuals are referred to buy xanax online as dual eligible beneficiaries.

The claw back provision is one of the most contentious elements of the Medicare Part D program. Given its financial ramifications, a number of States are questioning the accuracy of the federal estimates which form the basis of the payback calculations. Legal challenges by numerous States have been already announced.

Urix has partnered with Pharmacy Outcome Specialists, a firm with a national reputation for truly independent pharmacy program and PBM auditing, to deploy a specialized solution—dClaw to provide accurate assessment, monitoring and support of the clawback for individual states.

"This partnership combines Pharmacy Outcomes Specialists' reputation for buy phentermine online unbiased drug program audits with Urix' data acquisition and business intelligence capabilities to allow States to quickly and cost effectively verify their actual Part D clawback liability," said John Farrell, CEO of Urix. "

This BeyeNETWORK news item contains information from a recent press release by the company mentioned.